GTHR Debt-to-Equity -0.10 - GuruFocus.com
| GTHR Stock | USD 0.0001 0.00 0.00% |
Slightly above 56% of GeneThera's investor base is looking to short. The analysis of overall sentiment of trading GeneThera pink sheet suggests that many investors are alarmed at this time. GeneThera's investing sentiment overview a quick insight into current market opportunities from investing in GeneThera. Many technical investors use GeneThera stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
GeneThera pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of GeneThera daily returns and investor perception about the current price of GeneThera as well as its diversification or hedging effects on your existing portfolios.
GeneThera |
GTHR Debt-to-Equity -0.10 GuruFocus.com
Read at news.google.com
 |
GeneThera Fundamental Analysis
We analyze GeneThera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GeneThera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GeneThera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
GeneThera is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
GeneThera Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with GeneThera pink sheet to make a market-neutral strategy. Peer analysis of GeneThera could also be used in its relative valuation, which is a method of valuing GeneThera by comparing valuation metrics with similar companies.
Peers
GeneThera Related Equities
| VSTM | Verastem | 5.90 | ||||
| ELEV | Elevation Oncology | 0.29 | ||||
| RIGL | Rigel Pharmaceuticals | 0.14 | ||||
| IMMP | Immutep | 0.00 | ||||
| GERN | Geron | 0.33 |
Additional Tools for GeneThera Pink Sheet Analysis
When running GeneThera's price analysis, check to measure GeneThera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneThera is operating at the current time. Most of GeneThera's value examination focuses on studying past and present price action to predict the probability of GeneThera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneThera's price. Additionally, you may evaluate how the addition of GeneThera to your portfolios can decrease your overall portfolio volatility.